Sarepta price target raised to $150 from $148 at Guggenheim

Nov 7, 2024 · Guggenheim raised the firm’s price target on Sarepta (SRPT) to $150 from $148 and keeps a Buy rating on the shares. Elevidys and exon-skipping franchise sales were above …

$150
OFF

Sarepta Price Target Raised To $150 From $148 At Guggenheim

2 weeks from now

Nov 7, 2024 · Guggenheim raised the firm’s price target on Sarepta (SRPT) to $150 from $148 and keeps a Buy rating on the shares. Elevidys and exon-skipping franchise sales were above …

nasdaq.com

$148.00
OFF

Guggenheim Issues Positive Forecast For Sarepta Therapeutics …

2 weeks from now

Nov 10, 2024 · Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price target raised by Guggenheim from $148.00 to $150.00 in a research report released on Thursday,Benzinga …

mayfieldrecorder.com

$158.87
OFF

A Glimpse Into The Expert Outlook On Sarepta Therapeutics

2 weeks from now

Dec 19, 2024 · Analysts have recently evaluated Sarepta Therapeutics and provided 12-month price targets. The average target is $158.87, accompanied by a high estimate of $205.00 and …

nasdaq.com

23%
OFF

SRPT Stock Rises 23% In A Year: Time To Buy, Hold Or Sell?

2 weeks from now

Jan 6, 2025 · Estimates for Sarepta Therapeutics’ 2024 earnings per share (EPS) have risen from $1.48 to $2.17 in the past 60 days. Over the same timeframe, EPS estimates for 2025 have …

nasdaq.com

$183.00
OFF

Guggenheim Starts Sarepta Therapeutics (SRPT) At Buy

2 weeks from now

Dec 26, 2019 · Guggenheim analyst Whitney Ijem initiates coverage on Sarepta Therapeutics (NASDAQ: SRPT) with a Buy rating and a price target of $183.00.For an analyst ratings …

streetinsider.com

$168.79
OFF

Analyst Expectations For Sarepta Therapeutics's Future

2 weeks from now

Nov 25, 2024 · Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of $205.00, and a low estimate of $80.00.

nasdaq.com

74%
OFF

Sarepta Therapeutics (SRPT) Stock Price, News & Analysis

2 weeks from now

5 days ago · Earnings for Sarepta Therapeutics are expected to grow by 365.74% in the coming year, from $2.16 to $10.06 per share. Price to Earnings Ratio vs. the Market. The P/E ratio of …

marketbeat.com

$182.00
OFF

Sarepta Therapeutics Stock Supported By LGMD Pipeline Progress, …

2 weeks from now

1 day ago · On Tuesday, Piper Sandler reaffirmed its Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT) stock, maintaining a price target of $182.00. The endorsement follows …

investing.com

FAQs about Sarepta price target raised to $150 from $148 at Guggenheim Coupon?

Are Guggenheim stock recommendations accurate?

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Guggenheim. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. ...

Should you buy Sarepta (SRPT)?

The disconnect between Sarepta’s current valuation and its stock price suggests substantial room for growth, reinforcing the recommendation for investors to consider buying SRPT shares. In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $203.00 price target. ...

What was Sarepta Therapeutics' stock price on January 1st 2025?

Sarepta Therapeutics' stock was trading at $121.59 on January 1st, 2025. Since then, SRPT shares have increased by 3.2% and is now trading at $125.52. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its quarterly earnings results on Wednesday, August, 7th. ...

How did Sarepta Therapeutics (SRPT) perform in a quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its quarterly earnings results on Wednesday, August, 7th. The biotechnology company reported $0.07 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.06. The business's quarterly revenue was up 38.9% compared to the same quarter last year. ...

Is marketbeat endorsed by Guggenheim?

MarketBeat and its parent company are in no way affiliated with or endorsed by Guggenheim. Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. Yum! Brands ...

Is Sarepta Therapeutics a good stock to buy?

5.85% of the outstanding shares of Sarepta Therapeutics have been sold short. Sarepta Therapeutics has a short interest ratio ("days to cover") of 5.8. Short interest in Sarepta Therapeutics has recently decreased by 3.95%, indicating that investor sentiment is improving. Sarepta Therapeutics does not currently pay a dividend. ...